We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Sarepta, other biotech stocks tumble as FDA appoints new CBER director ...

Anant Ambani, Director, Reliance Industries Limited, along with his wife Radhika Merchant, performed Ganga Puja at Har Ki Pauri in Uttarakhand's Haridwar on Sunday. Anant Ambani, son of ...

Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees. In the ...

Buckner was speaking last month at Life Science Innovation Northwest, Seattle’s marquee gathering of the biotech industry. Most years, the two-day conference sees scientists, investors and other ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

the Rahway-based company announced April 29. The Merck Wilmington Biotech facility will house laboratory, manufacturing and warehouse capabilities for the launch and commercial production of ...

His ousting of Peter Marks—a senior official at the Food and Drug Administration and key proponent of faster drug approvals—sent biotech stocks tumbling last month and stoked concerns that the ...

Passed by the House in September 2024, the Biosecure Act took a particularly hardline stance on Chinese biotech, denying top firms access to U.S. pharma supply chains. The bill forced U.S ...

“The job market,” he said, “was terrible.” What we’re witnessing may be a remaking of biotech — surprising even to those in the industry. After five months of searching, Albert ...

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., while barring companies from working ...